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the use of other antibiotics. We conducted a subsequent
study to determine the impact of the policy on resistance
rates.
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OBJECTIVE: It has been asserted that “decisions regard-
ing the allocation of public HIV prevention funds repre-
sent the single most important set of HIV prevention
decisions made,” (Ruiz et al., 2000; p.19). As a result,
several approaches to allocating these funds have been
proposed. However, the application of these models is
limited because the measurements of performance are
usually not quantiﬁable in real practice. This research
outlines a resource allocation model that can be used 
to assist decision-makers in allocating HIV prevention
funds. METHODS: The current process of allocating
HIV prevention funds within various states was reviewed
in detail. Speciﬁcally, population subgroup, intervention,
and geographical issues were considered. In addition,
measures of successful intervention implementation were
identiﬁed. After this thorough review, parameters (i.e.,
prevalence, infectivity, input from local planning groups)
deemed to be important in determining the proper allo-
cation of funds were identiﬁed. These parameter choices
were guided by the need to be able to estimate parame-
ter values from available data systems. Using linear pro-
gramming techniques, a model based on our parameter
choices was developed for used by decision-makers that
incorporates a quantiﬁable measure of success. This
model also includes funding and equity constraints.
RESULTS: An allocation of funds can be made such that
several system constraints can be considered and the
model can be validated through prospective data collec-
tion. The model was programmed in Microsoft Excel®
with a user-friendly interface and was prototyped within
a state health department’s allocation system.
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OBJECTIVES: Current guidelines recommend pravas-
tatin or atorvastatin, and not lovastatin or simvastatin,
to avoid drug interactions in PI-treated HIV+ patients
requiring dyslipidemia treatment. Because limited data
are currently available on the historical management 
of dyslipidemia within the PI-treated HIV+ population,
we examined the annual utilization trend of non-
recommended HMG-CoA reductase inhibitors (statins)
within this population. METHODS: This was a retro-
spective, cross-sectional analysis using pharmacy claims
from 1998–2001 from a managed care organization
(MCO) of about 3.5 million lives. Patients with at least
2 claims for antiretroviral therapy with a cumulative
days’ supply >30 and concurrent statin-PI utilization
during the same calendar year were included. Logistic
regression was used to evaluate whether age, gender, 
or physician specialty were associated with non-
recommended statin use. RESULTS: There were 4 non-
mutually exclusive yearly cohorts with 492 unique HIV+
patients with concurrent statin-PI therapy (1998 :n = 141;
1999 :n = 224; 2000 :n = 231; 2001 :n = 250). Mean ages
ranged from 45.7–47.3 years and >95% were male. There
were 58 occurrences (6.9%) of concurrent simvastatin-PI
utilization between 1998–2001. No concurrent lovas-
tatin-PI was identiﬁed. Most patients (72.5%) received
their statins and PI from the same physician. Patients
receiving these medications from different physicians
were signiﬁcantly more likely to have concurrent simvas-
tatin-PI utilization (OR: 2.01, 95% CI: 1.13–3.58).
Although no overall trend in simvastatin-PI utilization
was observed, a signiﬁcant decreasing trend was seen
among infectious disease (ID) physicians (p = 0.04).
CONCLUSIONS: As this patient population and its
longevity grow, the quality of their management becomes
increasingly important. Since simvastatin and lovastatin
were not on this MCO’s formulary, the prevalence of non-
recommended statin use was low. Nevertheless, we found
a proportion of patients who received concurrent sim-
vastatin-PI and a decreasing utilization trend among ID
physicians as guidelines became better established.
Awareness, however, among non-ID physicians may still
need to be improved and greater coordination established
between different physician prescribers of statin and PI
therapy.
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OBJECTIVES: To assess potential implications of 
applying four competing national guidelines addressing
antibiotic prophylaxis of Total Hip Replacement (THR)
surgery. METHODS: Four guidelines were applied to a
random sample of 386 medical records of patients who
underwent THR surgery from January 1999 to Decem-
ber 2000. Setting: Orthopaedic surgery wards in a 2200-
bed French teaching hospital. Main outcome measure:
Compliance of physician practice with the French guide-
line (French National Agency of Accreditation and Health
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Evaluation), the Canadian guideline (Canadian Infectious
Disease Society), the US guideline (Infectious Diseases
Society of America), the South African guideline (South
African Drug Action Programme) and the Belgian guide-
line (Belgian Hygiene Committee) was assessed by an
independent investigator, according to the following 
criteria: antibiotic prophylaxis use, antimicrobial agent,
dosage of ﬁrst injection, time elapsed between ﬁrst injec-
tion and incision, total duration of antibiotic prophylaxis.
Interguideline agreement was assessed by using the Kappa
coefﬁcient. RESULTS: Overall compliance of physician
practice varied widely from 69% of patients for the 
Canadian guideline to 16% for the Belgian guideline
(compliance with the US guideline, the French guideline
and the South African guideline was respectively: 62%,
53% and 19%) (Kappa = 0.36; p < 0.01). These varia-
tions were principally due to the differences between
guidelines in the screening of Methicillin-Resistant
Staphylococcus aureus (MRSA) carriage and in the choice
of antimicrobial agent. CONCLUSIONS: Our ﬁndings
emphasize substantial discrepancies between national
guidelines from different countries. National experts
should take into account evidence-based data when
drawing up recommendations.
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OBJECTIVES: Although ﬁgures on the evolution of pre-
scriptions of ARV are now available, little is known about
the dynamics and reasons of treatment changes. The
STAR cohort was initiated in February 2001 across 3
French HIV Public Hospital to monitor and to explain
the evolution of ARV therapies. METHODS: STAR is an
observational study implemented to prospectively collect
electronic data on anti-HIV treatments, immunological
and virological status and medical cost of a random
sample of patients. It aims at identifying therapeutic
strategies in the setting of clinical practice. RESULTS: A
total of 1177 patients (77% male) were included, of mean
age 41 ± 9 years. A total of 290 patients (24.6%) had
clinical AIDS. Mean CD4 counts and viral load were
respectively 478 ± 275/mm3 and 29,300 ± 89,400
copies/ml in February 2001 versus 506 ± 283/mm3 and
15,300 ± 55,600 copies/ml in December 2002. Of the
whole cohort, 17% were ARV naïve in February 2001,
among whom 52.5% initiated an ARV treatment during
the observation period. The most frequent association in
February 2001 was 2 Nucleoside Reverse Transcriptase
Inhibitors (NRTI) + 1 Protease Inhibitor (PI) with 24.2%
of subjects, and in December 2002 2 NRTIs + 1 Non
Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
with 21.4%. Among emerging treatment schemes,
boosted PIs raised from 13.8% to 24.1%. Sixty percent
of patients had their regimen changed at least once over
the 21-month period. Main reasons of treatment changes
were toxicity (22%) and failure (21%). Among treatment
discontinuations, 32% were attributable to supervised
treatment interruption, 24% to toxicity and 14% to
patient’s decision. CONCLUSIONS: These preliminary
results obtained after 21 months of follow-up of the
STAR cohort show signiﬁcant trends in the changes of
treatment regimens with more simpliﬁed regimens and
more frequent multiple therapies. These ﬁndings could
help policy makers in the elaboration of guidelines and
the evaluation of adherence behavior.
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OBJECTIVE: This paper examines to analyze what deter-
mines the demand for vaccination in the elderly as a high
risk group. Then, by using the estimation results, this
paper evaluate how the law recommendation and/or
subsidy affect their demand. METHOD: Original data
were obtained from two surveys to the elders living with
descendants and the elders living without descendants,
conducted by the author. The survey contains the infor-
mation about the elders, the household, experience of
inﬂuenza during the last season and immunization during
and hypothetical questionnaire about immunization for
Conjoint Analysis. The three estimations are performed
for actual behavior; Conjoint Analysis and Joint Estima-
tion which combine the ﬁrst two estimation. RESULT:
Among estimation results, cost, number of immunization,
immunization in night or weekend, and law recommen-
dation heavily affect their demand. Experience of
inﬂuenza and immunization in the last season are the
most important determinants. Moreover, the superior of
the Joint Estimation is conﬁrmed. CONCLUSION: The
estimation results imply that about 8.9 million elders will
demand for vaccination if there is no cost and if there is
a law recommendation. Conversely, it will reduce to 3.2
million if cost is 6000yen (about $50 US dollars) and
without law recommendation. The change from no cost
to just 500yen (about $4 US dollars) depresses the
demand by 1.6 million elders. Law recommendation
alone can push up 2.0 million elders.
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